Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937649 | 1.00 | RORC (0.44) | RORCBCHEMAOBS1PR5S1PR1 | |
| SCHEMBL3369882 | 0.90 | GBA1 (0.51) | BCHEMAOBS1PR5S1PR1CYP3A4 | |
| SCHEMBL13105233 | 0.90 | GBA1 (0.51) | BCHEMAOBS1PR5S1PR1CYP3A4 | |
| SCHEMBL3369886 | 0.90 | GBA1 (0.51) | BCHEMAOBS1PR5S1PR1CYP3A4 | |
| SCHEMBL2934828 | 0.83 | MAPT (0.52) | RORCBCHEMAOBS1PR5S1PR1 | |
| SCHEMBL2936516 | 0.83 | MAPT (0.52) | RORCBCHEMAOBS1PR5S1PR1 | |
| SCHEMBL2934827 | 0.83 | MAPT (0.52) | RORCBCHEMAOBS1PR5S1PR1 | |
| SCHEMBL8226016 | 0.81 | S1PR5 (0.55) | RORCS1PR5S1PR1ALDH1A1GBA1 | |
| SCHEMBL2935926 | 0.81 | S1PR5 (0.55) | RORCS1PR5S1PR1ALDH1A1GBA1 | |
| SCHEMBL3912727 | 0.81 | S1PR5 (0.55) | RORCS1PR5S1PR1ALDH1A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | RORC 1425/4885BCHE 676/4885MAOB 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.